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Background
The diagnostic dilemma of patients suffering from chronic
obstructive pulmonary disease (COPD) presenting with
symptoms equivalent to an acute coronary syndrome
(ACS) and slightly elevated high sensitive troponine in the
observational range (hsTnT 14-53 ng/l) is complex. Prog-
nostic impact of elevated hsTnT demand further investiga-
tion. Comorbidities of COPD and coronary artery disease
are frequent, risk factors congruent. The acute setting
demands a safe and easily conductible test to identify
coronary problems reliably. Echocardiographic imaging
quality is often low due to emphysema. Adenosine is con-
traindicated due to its bronchospasmic effect. The new
vasodilatator regadenoson does not bear this limitation.
This study aims to evaluate feasibility and prognostic
power of regadenoson stress cMRI in the above described
population.
Methods
Twenty-two patients (70 ± 13 yo) with COPD GOLD
grade I-III presenting with ACS and elevated hsTnT in the
observational range (23 ± 9 ng/l) were enrolled. Prior to
coronary catheterization, they underwent cMRI with rega-
denoson-stress (400 μg i.v. bolus). Scans were conducted
on a Philips Achieva 1.5 T MRI, including CINE-
sequences, T2-imaging, late enhancement imaging, pul-
monary angiography as well as rest and stress myocardial
perfusion measurements. All Patients received pulmonary
function testing before and after regadenoson. All scans
were conducted within 48 hours after presentation.
Results
No adverse effect of regadenoson was observed. Pul-
monary function testing revealed a slight but not signifi-
cant amelioration after regadenoson (FEV1 pre and post
MRI: 67% and 73%, p = ns).
Quality of the scans remained unhampered by the emer-
gency management. All scans were conducted within 48
hours after presentation, also allowing consecutive coron-
ary catheterization within this time frame. Regadenoson
elevated heart rate and rate-pressure-product significantly
by 30%. In eight patients, stress cMRI detected myocardial
ischemia. In all these patients, coronary catheterization
revealed relevant coronary stenoses necessitating interven-
tion. In all cases, the respective vessel was correctly pre-
dicted by cMRI. One patient could not be intervened due
to a very small diameter of the target vessel. Whenever
cMRI detected no myocardial ischemia, coronary catheter-
ization revealed no coronary stenosis. We found positive
and negative predictive values of cMRI with regadenoson-
stress at 100% in our population.
Conclusions
Cardiac stress MRI proved safe, feasible in a limited
timeframe and of high predictive accuracy in our study.
Regadenoson did not deteriorate pulmonary function.
The quality of cMRI scans and analysis did not suffer
from the emergency setting and positive and negative
predictive values were 100% when determining the need
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for coronary revascularisation and predicting the target
vessel.
This method is ready to be implemented in a differen-
tiated management of patients with COPD and slightly
elevated hsTnT.
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